- Home
- TCRT vs CERO Comparison
TCRT vs CERO Comparison
Compare TCRT & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- CERO
- Stock Information
- Founded
- TCRT 1998
- CERO 2017
- Country
- TCRT United States
- CERO United States
- Employees
- TCRT N/A
- CERO N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- TCRT Health Care
- CERO
- Exchange
- TCRT Nasdaq
- CERO Nasdaq
- Market Cap
- TCRT 3.8M
- CERO 3.2M
- IPO Year
- TCRT N/A
- CERO N/A
- Fundamental
- Price
- TCRT $3.03
- CERO $0.45
- Analyst Decision
- TCRT
- CERO Buy
- Analyst Count
- TCRT 0
- CERO 2
- Target Price
- TCRT N/A
- CERO $3.00
- AVG Volume (30 Days)
- TCRT 12.3K
- CERO 993.4K
- Earning Date
- TCRT 05-15-2025
- CERO 05-15-2025
- Dividend Yield
- TCRT N/A
- CERO N/A
- EPS Growth
- TCRT N/A
- CERO N/A
- EPS
- TCRT N/A
- CERO N/A
- Revenue
- TCRT $11,000.00
- CERO N/A
- Revenue This Year
- TCRT $5,680,500.00
- CERO N/A
- Revenue Next Year
- TCRT N/A
- CERO N/A
- P/E Ratio
- TCRT N/A
- CERO N/A
- Revenue Growth
- TCRT 83.33
- CERO N/A
- 52 Week Low
- TCRT $1.31
- CERO $0.40
- 52 Week High
- TCRT $11.00
- CERO $102.00
- Technical
- Relative Strength Index (RSI)
- TCRT 60.98
- CERO 35.19
- Support Level
- TCRT $2.50
- CERO $0.42
- Resistance Level
- TCRT $2.80
- CERO $0.50
- Average True Range (ATR)
- TCRT 0.21
- CERO 0.05
- MACD
- TCRT 0.01
- CERO 0.00
- Stochastic Oscillator
- TCRT 98.31
- CERO 24.77
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.